Inhalte Newsletter2023s
Displaying 6641-6650 of 7032 results.
ID:
6789
Newsletter 2023: 655
Element: 13186
Position: 1
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;font-size:0"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/tages/tagesfrage_3.jpg" alt="Aktuelle Retaxfrage" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Aktuelle Retaxfrage"></td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">APOTHEKE FRAGT – DAP ANTWORTET</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Dürfen wir bei Mometason-Nasenspray zwischen OTC- und Rx-Produkt frei wählen?</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:15px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Uns liegt eine Verordnung über „N1 Mometason Spray 1–0–1“ vor. Wir stellen uns die Frage, ob wir bei der Abgabe zwischen OTC- und Rx-Arzneimittel frei wählen dürfen. Außerdem gibt es keine N1-Packung auf dem Markt.</p> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a target="_blank" href="https://www.deutschesapothekenportal.de/rezept-retax/apothekenfragen-archiv/vollstaendiger-beitrag/wahl-zwischen-otc-und-rx-produkt-bei-mometason-nasenspray/" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Lesen Sie hier die Antwort</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: vege – stock.adobe.com</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 13186
Position: 1
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;font-size:0"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/tages/tagesfrage_3.jpg" alt="Aktuelle Retaxfrage" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Aktuelle Retaxfrage"></td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">APOTHEKE FRAGT – DAP ANTWORTET</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Dürfen wir bei Mometason-Nasenspray zwischen OTC- und Rx-Produkt frei wählen?</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:15px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Uns liegt eine Verordnung über „N1 Mometason Spray 1–0–1“ vor. Wir stellen uns die Frage, ob wir bei der Abgabe zwischen OTC- und Rx-Arzneimittel frei wählen dürfen. Außerdem gibt es keine N1-Packung auf dem Markt.</p> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a target="_blank" href="https://www.deutschesapothekenportal.de/rezept-retax/apothekenfragen-archiv/vollstaendiger-beitrag/wahl-zwischen-otc-und-rx-produkt-bei-mometason-nasenspray/" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Lesen Sie hier die Antwort</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: vege – stock.adobe.com</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6790
Newsletter 2023: 655
Element: 13187
Position: 2
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/rezept-retax/retax-arbeitshilfen/rezeptpruefung/rezeptfaelschung/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_Arbeitshilfe-Rezeptfaelschungen.png" alt="Zur Arbeitshilfe" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Zur Arbeitshilfe"></a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 13187
Position: 2
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/rezept-retax/retax-arbeitshilfen/rezeptpruefung/rezeptfaelschung/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_Arbeitshilfe-Rezeptfaelschungen.png" alt="Zur Arbeitshilfe" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Zur Arbeitshilfe"></a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6791
Newsletter 2023: 655
Element: 13151
Position: 3
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:6px;padding-top:6px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Neues Generikum von STADA: Nintedanib IPF STADA<sup style="line-height:0;">®</sup> Weichkapseln</h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px;padding-bottom:0px;"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Am 10.04.2026 erweiterte STADA sein Generika-Portfolio um Nintedanib IPF STADA<sup style="line-height:0;">®</sup>. Erhältlich ist das Generikum in den Wirkstärken 100 mg und 150 mg. Das Arzneimittel ist zur Behandlung der idiopathischen Lungenfibrose (IPF) bei Erwachsenen zugelassen.</p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Aufgrund der Teilnahme an zahlreichen Open-House-Verträgen kann Nintedanib IPF STADA<sup style="line-height:0;">®</sup> Weichkapseln als Rabattarzneimittel an viele gesetzlich Versicherte abgegeben werden.</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><img class="adapt-img" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2026q1/newsletter_2026-03-29_g1.jpg"></td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© STADAPHARM GmbH</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#e0e0e0;width:660px" cellspacing="0" cellpadding="0" bgcolor="#e0e0e0" align="center"> <tbody> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:20px;padding-top:20px;background-color:#ffffff"> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.stada.de/produkte/nintedanib-ipf-stada" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Weitere Informationen*</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px" class="pt-20"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#eeeeee"><a href="https://www.deutschesapothekenportal.de/beratung/beratungswissen/nintedanib/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #000; text-decoration: none;background-color: #eeeeee; padding: 10px 20px; border: 1px solid #eeeeee; display: block;">Zum Beratungswissen</a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:5px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">*Login erforderlich</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:5px;padding-bottom:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">» <a href="https://www.deutschesapothekenportal.de/newsletter/2026q2/pt_nintedanib-ipf-stada.pdf" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:11px;color:#005CA9;word-break:break-all;">Pflichttext (PDF)</a></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 13151
Position: 3
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:6px;padding-top:6px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Neues Generikum von STADA: Nintedanib IPF STADA<sup style="line-height:0;">®</sup> Weichkapseln</h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px;padding-bottom:0px;"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Am 10.04.2026 erweiterte STADA sein Generika-Portfolio um Nintedanib IPF STADA<sup style="line-height:0;">®</sup>. Erhältlich ist das Generikum in den Wirkstärken 100 mg und 150 mg. Das Arzneimittel ist zur Behandlung der idiopathischen Lungenfibrose (IPF) bei Erwachsenen zugelassen.</p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Aufgrund der Teilnahme an zahlreichen Open-House-Verträgen kann Nintedanib IPF STADA<sup style="line-height:0;">®</sup> Weichkapseln als Rabattarzneimittel an viele gesetzlich Versicherte abgegeben werden.</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><img class="adapt-img" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2026q1/newsletter_2026-03-29_g1.jpg"></td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© STADAPHARM GmbH</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#e0e0e0;width:660px" cellspacing="0" cellpadding="0" bgcolor="#e0e0e0" align="center"> <tbody> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:20px;padding-top:20px;background-color:#ffffff"> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.stada.de/produkte/nintedanib-ipf-stada" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Weitere Informationen*</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px" class="pt-20"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#eeeeee"><a href="https://www.deutschesapothekenportal.de/beratung/beratungswissen/nintedanib/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #000; text-decoration: none;background-color: #eeeeee; padding: 10px 20px; border: 1px solid #eeeeee; display: block;">Zum Beratungswissen</a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:5px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">*Login erforderlich</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:5px;padding-bottom:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">» <a href="https://www.deutschesapothekenportal.de/newsletter/2026q2/pt_nintedanib-ipf-stada.pdf" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:11px;color:#005CA9;word-break:break-all;">Pflichttext (PDF)</a></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6792
Newsletter 2023: 655
Element: 12815
Position: 4
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/wissen/dap-fortbildungen/hormonelle-kontrazeptiva-in-der-selbstanwendung/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_DAP-Fortbildung-Orale-Kontrazeptiva.jpg" alt="DAP FORTBILDUNG Orale Kontrazeptiva" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="DAP FORTBILDUNG Orale Kontrazeptiva"></a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 12815
Position: 4
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/wissen/dap-fortbildungen/hormonelle-kontrazeptiva-in-der-selbstanwendung/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_DAP-Fortbildung-Orale-Kontrazeptiva.jpg" alt="DAP FORTBILDUNG Orale Kontrazeptiva" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="DAP FORTBILDUNG Orale Kontrazeptiva"></a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6793
Newsletter 2023: 655
Element: 13188
Position: 5
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">AKTUELLES</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Neuer Borreliose-Impfstoffkandidat in der Pipeline</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px;"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#005ca9">Phase-III-Studie liefert gute Daten</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px"><b>Ein Impfstoff gegen Lyme-Borreliose rückt näher: Der Kandidat PF-07307405 (LB6V), entwickelt von Pfizer und Valneva, zeigt in der Phase-3-Studie VALOR eine Wirksamkeit von über 70 % bei Personen ab 5 Jahren. Damit könnte erstmals eine gezielte Prävention gegen die häufigste durch Zecken übertragene Infektion auf der Nordhalbkugel verfügbar werden.</b></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">In der VALOR-Studie, einer multizentrischen, placebokontrollierten, randomisierten und beobachterverblindeten Studie, wurden die Teilnehmerinnen und Teilnehmer ab 5 Jahren 1:1 in zwei Gruppen randomisiert. Die Verum-Gruppe erhielt vier Dosen des Impfstoffkandidaten in den Monaten 0, 2 und 5–9 und eine vierte Dosis nach einem Jahr kurz vor Beginn der darauffolgenden Borreliose-Saison. Die Placebogruppe erhielt zu den gleichen Zeitpunkten eine Kochsalzlösung.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">In den vorab definierten Analysen lag die Wirksamkeit bzgl. der Reduktion bestätigter Borreliose-Fälle im Vergleich zum Placeboarm bei 73,2 % ab 28 Tagen nach der 4. Dosis bzw. bei 74,8 % ab einem Tag nach der 4. Dosis. Der Impfstoff wurde zudem gut vertragen, und es wurden keine sicherheitsrelevanten Auffälligkeiten beobachtet.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Während des Studienzeitraums traten weniger Fälle von Lyme-Borreliose auf als erwartet und das vorab festgelegte statistische Kriterium für den primären Endpunkt (Untergrenze des 95-%-Konfidenzintervalls > 20 %) wurde beim ersten von zwei vorab festgelegten Analysezeitpunkten nicht erreicht. Dennoch werten die Hersteller die Ergebnisse als klinisch relevant und sehen das Potenzial des Impfstoffs bestätigt. Entsprechende Zulassungsanträge in den USA und Europa sind geplant.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Der Impfstoff basiert auf einem etablierten Wirkprinzip: Er richtet sich gegen das Oberflächenprotein A (OspA) von <i>Borrelia burgdorferi</i>. Wenn eine Zecke eine geimpfte Person sticht, werden die gebildeten Antikörper mit dem Blut der Person aufgenommen und blockieren die Übertragung der Erreger bereits im Zeckendarm. Die Bakterien können die Zecke nicht verlassen und somit wird die Übertragung auf den Menschen verhindert. Der Kandidat deckt sechs relevante Serotypen ab, die in Europa und Nordamerika verbreitet sind.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:20px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Borreliose ist die häufigste vektorübertragene Erkrankung der nördlichen Hemisphäre. Frühzeichen wie Erythema migrans oder unspezifische Symptome wie Müdigkeit, Fieber, Kopfschmerzen und Muskel- und Gelenkschmerzen werden häufig übersehen. Unbehandelt kann es zu chronischen Verläufen mit Beteiligung von Gelenken, Herz oder Nervensystem kommen.</p> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Quellen:<br>Pfizer: Pressemitteilung „Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial“ Stand 23.03.2026. Online abrufbar unter: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-announce-lyme-disease-vaccine-candidate</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 13188
Position: 5
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">AKTUELLES</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Neuer Borreliose-Impfstoffkandidat in der Pipeline</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px;"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#005ca9">Phase-III-Studie liefert gute Daten</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px"><b>Ein Impfstoff gegen Lyme-Borreliose rückt näher: Der Kandidat PF-07307405 (LB6V), entwickelt von Pfizer und Valneva, zeigt in der Phase-3-Studie VALOR eine Wirksamkeit von über 70 % bei Personen ab 5 Jahren. Damit könnte erstmals eine gezielte Prävention gegen die häufigste durch Zecken übertragene Infektion auf der Nordhalbkugel verfügbar werden.</b></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">In der VALOR-Studie, einer multizentrischen, placebokontrollierten, randomisierten und beobachterverblindeten Studie, wurden die Teilnehmerinnen und Teilnehmer ab 5 Jahren 1:1 in zwei Gruppen randomisiert. Die Verum-Gruppe erhielt vier Dosen des Impfstoffkandidaten in den Monaten 0, 2 und 5–9 und eine vierte Dosis nach einem Jahr kurz vor Beginn der darauffolgenden Borreliose-Saison. Die Placebogruppe erhielt zu den gleichen Zeitpunkten eine Kochsalzlösung.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">In den vorab definierten Analysen lag die Wirksamkeit bzgl. der Reduktion bestätigter Borreliose-Fälle im Vergleich zum Placeboarm bei 73,2 % ab 28 Tagen nach der 4. Dosis bzw. bei 74,8 % ab einem Tag nach der 4. Dosis. Der Impfstoff wurde zudem gut vertragen, und es wurden keine sicherheitsrelevanten Auffälligkeiten beobachtet.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Während des Studienzeitraums traten weniger Fälle von Lyme-Borreliose auf als erwartet und das vorab festgelegte statistische Kriterium für den primären Endpunkt (Untergrenze des 95-%-Konfidenzintervalls > 20 %) wurde beim ersten von zwei vorab festgelegten Analysezeitpunkten nicht erreicht. Dennoch werten die Hersteller die Ergebnisse als klinisch relevant und sehen das Potenzial des Impfstoffs bestätigt. Entsprechende Zulassungsanträge in den USA und Europa sind geplant.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Der Impfstoff basiert auf einem etablierten Wirkprinzip: Er richtet sich gegen das Oberflächenprotein A (OspA) von <i>Borrelia burgdorferi</i>. Wenn eine Zecke eine geimpfte Person sticht, werden die gebildeten Antikörper mit dem Blut der Person aufgenommen und blockieren die Übertragung der Erreger bereits im Zeckendarm. Die Bakterien können die Zecke nicht verlassen und somit wird die Übertragung auf den Menschen verhindert. Der Kandidat deckt sechs relevante Serotypen ab, die in Europa und Nordamerika verbreitet sind.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:20px;padding-left:20px;padding-top:20px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Borreliose ist die häufigste vektorübertragene Erkrankung der nördlichen Hemisphäre. Frühzeichen wie Erythema migrans oder unspezifische Symptome wie Müdigkeit, Fieber, Kopfschmerzen und Muskel- und Gelenkschmerzen werden häufig übersehen. Unbehandelt kann es zu chronischen Verläufen mit Beteiligung von Gelenken, Herz oder Nervensystem kommen.</p> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Quellen:<br>Pfizer: Pressemitteilung „Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial“ Stand 23.03.2026. Online abrufbar unter: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-announce-lyme-disease-vaccine-candidate</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6794
Newsletter 2023: 655
Element: 13183
Position: 6
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/beratung/beratungswissen/ivermectin-in-der-rosazea-therapie/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_Beratungswissen_Ivermectin.png" alt="Zum Beratungswissen" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Zum Beratungswissen"></a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 13183
Position: 6
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/beratung/beratungswissen/ivermectin-in-der-rosazea-therapie/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_Beratungswissen_Ivermectin.png" alt="Zum Beratungswissen" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Zum Beratungswissen"></a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6795
Newsletter 2023: 655
Element: 13189
Position: 7
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">DAZ.ONLINE INFORMIERT</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#005ca9">Studienergebnisse hinterfragt</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:28px;color:#005CA9">Kreatin kann doch keine Kognition</h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Kreatin lässt die Kognition kalt – anders als eine vielzitierte Metaanalyse von 2024 uns bislang glauben machte. Allerdings hatten sich die damaligen Studienautorinnen und -autoren wohl verrechnet.</p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Kraftsport und Kreatin passen zusammen – denn: Kreatin unterstützt die Muskelkraft bei Widerstandstraining. Doch Kreatin soll viel mehr können: Einer früheren Metaanalyse zufolge könnten Kreatin-Supplements bei Erwachsenen die kognitive Funktion unterstützen – Gedächtnis, Reaktionszeit, Informations­verarbeitungs­geschwindigkeit.</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><sup><img class="adapt-img" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2026q2/newsletter_2026-04-30_g1.jpg"></sup></td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">Karin & Uwe Annas – stock.adobe.com</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.deutsche-apotheker-zeitung.de/news/artikel/2026/04/28/kreatin-kann-doch-keine-kognition" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Mehr auf DAZ.online</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 13189
Position: 7
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">DAZ.ONLINE INFORMIERT</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#005ca9">Studienergebnisse hinterfragt</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:28px;color:#005CA9">Kreatin kann doch keine Kognition</h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Kreatin lässt die Kognition kalt – anders als eine vielzitierte Metaanalyse von 2024 uns bislang glauben machte. Allerdings hatten sich die damaligen Studienautorinnen und -autoren wohl verrechnet.</p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Kraftsport und Kreatin passen zusammen – denn: Kreatin unterstützt die Muskelkraft bei Widerstandstraining. Doch Kreatin soll viel mehr können: Einer früheren Metaanalyse zufolge könnten Kreatin-Supplements bei Erwachsenen die kognitive Funktion unterstützen – Gedächtnis, Reaktionszeit, Informations­verarbeitungs­geschwindigkeit.</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><sup><img class="adapt-img" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2026q2/newsletter_2026-04-30_g1.jpg"></sup></td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">Karin & Uwe Annas – stock.adobe.com</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.deutsche-apotheker-zeitung.de/news/artikel/2026/04/28/kreatin-kann-doch-keine-kognition" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Mehr auf DAZ.online</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6796
Newsletter 2023: 655
Element: 13185
Position: 8
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:5px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"> <span style="background:transparent">Anzeige</span> </p> </td> </tr> <tr> <td align="left" style="padding:0;Margin:0;font-size:0"> <img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/2023q3/newsletter_2023-08-19_g2.jpg" alt="Apofrage des Tages" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title=""> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555"> APOFRAGE DES TAGES</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:28px;color:#005CA9">Für welche der folgenden Erkrankungen ist Nintedanib AL zugelassen?</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Bei richtiger Antwort werden Ihnen 5 DAPs-Punkte gutgeschrieben.</p> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#e0e0e0;width:660px" cellspacing="0" cellpadding="0" bgcolor="#e0e0e0" align="center"> <tbody> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:20px;padding-top:20px;background-color:#ffffff"> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.deutschesapothekenportal.de/wissen/apofrage-des-tages/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Zur Apofrage des Tages</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px" class="pt-20"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#eeeeee"><a href="https://www.meindap.de/apofrage_2026-04-30_nintedanib_info" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #000; text-decoration: none;background-color: #eeeeee; padding: 10px 20px; border: 1px solid #eeeeee; display: block;">Mehr zu Nintedanib AL*</a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">* Login erforderlich</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">» <a href="https://www.meindap.de/apofrage_2026-04-30_nintedanib_pt" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:11px;color:#005CA9;word-break:break-all;">Pflichttext (PDF)</a></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: DAP Networks GmbH</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table></td></tr></tbody></table>
Newsletter 2023: 655
Element: 13185
Position: 8
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:5px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"> <span style="background:transparent">Anzeige</span> </p> </td> </tr> <tr> <td align="left" style="padding:0;Margin:0;font-size:0"> <img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/2023q3/newsletter_2023-08-19_g2.jpg" alt="Apofrage des Tages" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title=""> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555"> APOFRAGE DES TAGES</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:28px;color:#005CA9">Für welche der folgenden Erkrankungen ist Nintedanib AL zugelassen?</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:20px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Bei richtiger Antwort werden Ihnen 5 DAPs-Punkte gutgeschrieben.</p> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#e0e0e0;width:660px" cellspacing="0" cellpadding="0" bgcolor="#e0e0e0" align="center"> <tbody> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:20px;padding-top:20px;background-color:#ffffff"> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.deutschesapothekenportal.de/wissen/apofrage-des-tages/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Zur Apofrage des Tages</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:300px" class="pt-20"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#eeeeee"><a href="https://www.meindap.de/apofrage_2026-04-30_nintedanib_info" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #000; text-decoration: none;background-color: #eeeeee; padding: 10px 20px; border: 1px solid #eeeeee; display: block;">Mehr zu Nintedanib AL*</a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">* Login erforderlich</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">» <a href="https://www.meindap.de/apofrage_2026-04-30_nintedanib_pt" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:11px;color:#005CA9;word-break:break-all;">Pflichttext (PDF)</a></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: DAP Networks GmbH</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table></td></tr></tbody></table>
ID:
6797
Newsletter 2023: 655
Element: 9923
Position: 9
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;padding-left:20px;"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#e0e0e0;width:660px" cellspacing="0" cellpadding="0" bgcolor="#e0e0e0" align="center"> <tbody> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:20px;padding-top:20px;background-color:#ffffff"> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:380px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px"><strong>Hinweis:</strong> Anregungen, Kritik und Themenwünsche zum Newsletter können gerne per Mail an <a href="mailto:info@deutschesapothekenportal.de" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9">info@deutschesapothekenportal.de</a> geschickt werden<a href="https://www.meindap.de/apo-nl-cleverreach" target="_blank" style="color:#555555; text-decoration: none">.</a> Wir freuen uns auf Ihr Feedback!</a></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:180px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;font-size:0"><img src="https://www.deutschesapothekenportal.de/newsletter/icons/email_Icon.png" alt="Mail-Symbol" height="70" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none"></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 655
Element: 9923
Position: 9
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;padding-left:20px;"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#e0e0e0;width:660px" cellspacing="0" cellpadding="0" bgcolor="#e0e0e0" align="center"> <tbody> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:20px;padding-top:20px;background-color:#ffffff"> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:380px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px"><strong>Hinweis:</strong> Anregungen, Kritik und Themenwünsche zum Newsletter können gerne per Mail an <a href="mailto:info@deutschesapothekenportal.de" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9">info@deutschesapothekenportal.de</a> geschickt werden<a href="https://www.meindap.de/apo-nl-cleverreach" target="_blank" style="color:#555555; text-decoration: none">.</a> Wir freuen uns auf Ihr Feedback!</a></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:180px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;font-size:0"><img src="https://www.deutschesapothekenportal.de/newsletter/icons/email_Icon.png" alt="Mail-Symbol" height="70" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none"></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
ID:
6798
Newsletter 2023: 656
Element: 13191
Position: 1
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;font-size:0"> <img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/2023q4/newsletter_2023-10-02_g1.jpg" alt="Aktuelle Kurzumfrage" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title=""> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">AKTUELLE KURZUMFRAGE</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Thema: Nutzung der elektronischen Medikationsliste im Apothekenalltag</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Vor gut einem Jahr, am 29. April 2025, startete bundesweit die ePA für alle. Für Apotheken ist dabei insbesondere die elektronische Medikationsliste (eML) von Bedeutung: Sie bildet die Medikationshistorie von Patientinnen und Patienten über alle elektronisch verordneten und abgegebenen Arzneimittel ab. Bei eingesteckter Gesundheitskarte kann das Apothekenteam Einsicht nehmen und diese Informationen etwa zur Identifikation von Kontraindikationen und Wechselwirkungen nutzen.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px"><b>In welchen Fällen nutzen Sie in Ihrer Apotheke die elektronische Medikationsliste?</b></p> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/7bWyVojKzp/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Regelmäßig bei nahezu jeder Beratung mit Arzneimittelabgabe.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/djOjRn1O8y/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Vor allem bei Polymedikation bzw. komplexen Medikationsprofilen.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/2QWgebVOR4/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Nur gezielt bei Verdacht auf Wechselwirkungen oder Kontraindikationen.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/x7r5zQRWe5/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Nur in Einzelfällen (z. B. auf Nachfrage oder bei unklarer Medikation).</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/LpOGqw1WGz/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Selten – die eML spielt bislang kaum eine Rolle im Alltag.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/Q8rw2onONw/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Gar nicht – die eML wird in unserer Apotheke derzeit nicht genutzt.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:0px;padding-top:20px;background-color:#ffffff"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="Margin:0;padding-bottom:20px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Jetzt DAPs sammeln</h2> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:380px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-bottom:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Mit Ihrer Teilnahme werden Ihnen <strong>5 DAPs</strong> gutgeschrieben. Zusätzlich nehmen Sie an der Verlosung von <strong>1.000 DAPs</strong> teil.</p> </td> </tr> <tr> <td align="left" style="padding:0;Margin:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Sollten Sie sich noch nicht für das DAPs-Punktesystem angemeldet haben, können Sie sich hier registrieren: </p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:180px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;font-size:0"><img src="https://www.deutschesapothekenportal.de/newsletter/screen/5-daps-punkte.png" alt="5 DAPs-Punkte!" height="70" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none"></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.deutschesapothekenportal.de/registrierung-mein-dap/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Zur Registrierung</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: momius – stock.adobe.com</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Newsletter 2023: 656
Element: 13191
Position: 1
Html: <table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;font-size:0"> <img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/2023q4/newsletter_2023-10-02_g1.jpg" alt="Aktuelle Kurzumfrage" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title=""> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">AKTUELLE KURZUMFRAGE</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Thema: Nutzung der elektronischen Medikationsliste im Apothekenalltag</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Vor gut einem Jahr, am 29. April 2025, startete bundesweit die ePA für alle. Für Apotheken ist dabei insbesondere die elektronische Medikationsliste (eML) von Bedeutung: Sie bildet die Medikationshistorie von Patientinnen und Patienten über alle elektronisch verordneten und abgegebenen Arzneimittel ab. Bei eingesteckter Gesundheitskarte kann das Apothekenteam Einsicht nehmen und diese Informationen etwa zur Identifikation von Kontraindikationen und Wechselwirkungen nutzen.</p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px"><b>In welchen Fällen nutzen Sie in Ihrer Apotheke die elektronische Medikationsliste?</b></p> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/7bWyVojKzp/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Regelmäßig bei nahezu jeder Beratung mit Arzneimittelabgabe.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/djOjRn1O8y/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Vor allem bei Polymedikation bzw. komplexen Medikationsprofilen.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/2QWgebVOR4/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Nur gezielt bei Verdacht auf Wechselwirkungen oder Kontraindikationen.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/x7r5zQRWe5/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Nur in Einzelfällen (z. B. auf Nachfrage oder bei unklarer Medikation).</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/LpOGqw1WGz/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Selten – die eML spielt bislang kaum eine Rolle im Alltag.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 0px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td align="left" style="border-radius: 0px;line-height:20px;mso-line-height-rule:exactly; padding: 14px 20px;" bgcolor="#005CA9"><a href="https://www.deutschesapothekenportal.de/community/aktuelle-kurzumfrage/abstimmen/DLpOGvjKGz/Q8rw2onONw/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; border: 1px solid #005CA9; display: block;">Gar nicht – die eML wird in unserer Apotheke derzeit nicht genutzt.</a></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" style="Margin:0;padding-right:20px;padding-left:20px;padding-bottom:0px;padding-top:20px;background-color:#ffffff"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="Margin:0;padding-bottom:20px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Jetzt DAPs sammeln</h2> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:380px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-bottom:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Mit Ihrer Teilnahme werden Ihnen <strong>5 DAPs</strong> gutgeschrieben. Zusätzlich nehmen Sie an der Verlosung von <strong>1.000 DAPs</strong> teil.</p> </td> </tr> <tr> <td align="left" style="padding:0;Margin:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Sollten Sie sich noch nicht für das DAPs-Punktesystem angemeldet haben, können Sie sich hier registrieren: </p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:180px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;font-size:0"><img src="https://www.deutschesapothekenportal.de/newsletter/screen/5-daps-punkte.png" alt="5 DAPs-Punkte!" height="70" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none"></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.deutschesapothekenportal.de/registrierung-mein-dap/" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Zur Registrierung</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: momius – stock.adobe.com</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>